| Literature DB >> 32909238 |
Zacharie Saint-Georges1,2, Vanessa K Zayed3, Katie Dinelle4, Clifford Cassidy3, Jean-Paul Soucy5, Gassan Massarweh5, Benjamin Rotstein6,7, Pablo B Nery8, Synthia Guimond9,3,10,11, Robert deKemp7, Lauri Tuominen3,11.
Abstract
In contrast to cardiac sympathetic activity which can be assessed with established PET tracers, there are currently no suitable radioligands to measure cardiac parasympathetic (cholinergic) activity. A radioligand able to measure cardiac cholinergic activity would be an invaluable clinical and research tool since cholinergic dysfunction has been associated with a wide array of pathologies (e.g., chronic heart failure, myocardial infarction, arrythmias). [18F]Fluoroethoxybenzovesamicol (FEOBV) is a cholinergic radiotracer that has been extensively validated in the brain. Whether FEOBV PET can be used to assess cholinergic activity in the heart is not known. Hence, this study aimed to evaluate the properties of FEOBV for cardiac PET imaging and cholinergic activity mapping. PET data were collected for 40 minutes after injection of 230 ± 50 MBq of FEOBV in four healthy participants (1 female; Age: 37 ± 10; BMI: 25 ± 2). Dynamic LV time activity curves were fitted with Logan graphical, 1-tissue compartment, and 2-tissue compartment models, yielding similar distribution volume estimates for each participant. Our initial data show that FEOBV PET has favorable tracer kinetics for quantification of cholinergic activity and is a promising new method for assessing parasympathetic function in the heart.Entities:
Keywords: PET; Tracer development; innervation tracers; molecular imaging; molecular imaging agents
Mesh：
Substances：
Year: 2020 PMID： 32909238 PMCID： PMC7921026 DOI： 10.1007/s12350-020-02323-w
Source DB: PubMed Journal: J Nucl Cardiol ISSN： 1071-3581 Impact factor: 5.952